USADA announced today that Jordan Adel, of McKinney, Texas, an athlete in the sport of weightlifting, has accepted a three-year period of ineligibility for an anti-doping rule violation. Adel, 32, tested positive for ibutamoren, ostarine (enobosarm), and LGD-4033 (ligandrol) and its metabolite di-hydroxy-LGD-4033, as the result of an out-of-competition urine sample collected on October 12, 2021.

Ostarine and LGD-4033 are Non-Specified Substance in the class of Anabolic Agents, while ibutamoren is a Non-Specified Substance in the class of Peptide Hormones, Growth Factors, Related Substances, and Mimetics. These substances are prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic and Paralympic Committee National Anti-Doping Policy, and the International Weightlifting Federation Anti-Doping Rules, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List.

Under Article 10.8.1 of the 2021 Code, an athlete who faces an anti-doping rule violation that carries a period of ineligibility of four or more years may receive a one-year sanction reduction if the athlete admits the violation and accepts the asserted sanction within 20 days of notification of the alleged anti-doping rule violation charge. Per the rule, Adel qualified for a one-year reduction to the otherwise applicable four-year period of ineligibility.

Adel’s three-year period of ineligibility began on November 3, 2021, the date his provisional suspension was imposed. In addition, Adel has been disqualified from all competitive results obtained on and subsequent to October 12, 2021, the date his positive sample was collected, including forfeiture of any medals, points and prizes.

• This media release was published by the US Anti-Doping Agency (USADA) on 30 November 2021. Click here for the original.